BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 29105949)

  • 1. A model for predicting the dose to the parotid glands based on their relative overlapping with planning target volumes during helical radiotherapy.
    Millunchick CH; Zhen H; Redler G; Liao Y; Turian JV
    J Appl Clin Med Phys; 2018 Mar; 19(2):48-53. PubMed ID: 29105949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results.
    Chao KS; Deasy JO; Markman J; Haynie J; Perez CA; Purdy JA; Low DA
    Int J Radiat Oncol Biol Phys; 2001 Mar; 49(4):907-16. PubMed ID: 11240231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preservation of oral health-related quality of life and salivary flow rates after inverse-planned intensity- modulated radiotherapy (IMRT) for head-and-neck cancer.
    Parliament MB; Scrimger RA; Anderson SG; Kurien EC; Thompson HK; Field GC; Hanson J
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):663-73. PubMed ID: 14967418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using a reduced spot size for intensity-modulated proton therapy potentially improves salivary gland-sparing in oropharyngeal cancer.
    van de Water TA; Lomax AJ; Bijl HP; Schilstra C; Hug EB; Langendijk JA
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e313-9. PubMed ID: 21708427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of salivary gland function after treatment of head-and-neck tumors with intensity-modulated radiotherapy by quantitative pertechnetate scintigraphy.
    Münter MW; Karger CP; Hoffner SG; Hof H; Thilmann C; Rudat V; Nill S; Wannenmacher M; Debus J
    Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):175-84. PubMed ID: 14697436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parotid gland sparing with helical tomotherapy in head-and-neck cancer.
    Voordeckers M; Farrag A; Everaert H; Tournel K; Storme G; Verellen D; De Ridder M
    Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):443-8. PubMed ID: 22836056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simple tool for prediction of parotid gland sparing in intensity-modulated radiation therapy.
    Gensheimer MF; Hummel-Kramer SM; Cain D; Quang TS
    Med Dosim; 2015; 40(3):232-4. PubMed ID: 25704638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salivary gland sparing and improved target irradiation by conformal and intensity modulated irradiation of head and neck cancer.
    Eisbruch A; Ship JA; Dawson LA; Kim HM; Bradford CR; Terrell JE; Chepeha DB; Teknos TN; Hogikyan ND; Anzai Y; Marsh LH; Ten Haken RK; Wolf GT
    World J Surg; 2003 Jul; 27(7):832-7. PubMed ID: 14509515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A study on the impact of patient-related parameters in the ability to spare parotid glands by intensity-modulated radiotherapy for head and neck squamous cell carcinomas.
    Bandlamudi BP; Sharan K; Yathiraj PH; Singh A; Reddy A; Fernandes DJ; Srinivasa VM
    J Cancer Res Ther; 2018; 14(6):1220-1224. PubMed ID: 30488833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Importance of the initial volume of parotid glands in xerostomia for patients with head and neck cancers treated with IMRT.
    Nishimura Y; Nakamatsu K; Shibata T; Kanamori S; Koike R; Okumura M; Suzuki M
    Jpn J Clin Oncol; 2005 Jul; 35(7):375-9. PubMed ID: 15976068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can sparing of the superficial contralateral parotid lobe reduce xerostomia following radiotherapy for head and neck cancer?
    Nevens D; Nuyts S
    Br J Radiol; 2017 Dec; 90(1080):20170596. PubMed ID: 28972794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conformal and intensity modulated irradiation of head and neck cancer: the potential for improved target irradiation, salivary gland function, and quality of life.
    Eisbruch A; Dawson LA; Kim HM; Bradford CR; Terrell JE; Chepeha DB; Teknos TN; Anzai Y; Marsh LH; Martel MK; Ten Haken RK; Wolf GT; Ship JA
    Acta Otorhinolaryngol Belg; 1999; 53(3):271-5. PubMed ID: 10635407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of salivary gland dosimetry on post-IMRT recovery of saliva output and xerostomia grade for head-and-neck cancer patients treated with or without contralateral submandibular gland sparing: a longitudinal study.
    Wang ZH; Yan C; Zhang ZY; Zhang CP; Hu HS; Tu WY; Kirwan J; Mendenhall WM
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1479-87. PubMed ID: 20934262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Node Negative Target Volume Delineation on Contralateral Parotid Gland Dose Sparing Using IMRT in Head and Neck Cancer.
    Magnuson WJ; Urban E; Bayliss RA; Harari PM
    Technol Cancer Res Treat; 2015 Jun; 14(3):315-9. PubMed ID: 25782188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Geometric factors influencing dosimetric sparing of the parotid glands using IMRT.
    Hunt MA; Jackson A; Narayana A; Lee N
    Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):296-304. PubMed ID: 16904529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3D-conformal-intensity modulated radiotherapy with compensators for head and neck cancer: clinical results of normal tissue sparing.
    Wendt TG; Abbasi-Senger N; Salz H; Pinquart I; Koscielny S; Przetak SM; Wiezorek T
    Radiat Oncol; 2006 Jun; 1():18. PubMed ID: 16790059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Presentation of a 3D conformal radiotherapy technique for head-and-neck tumors resulting in substantial protection of the parotid glands].
    Kuhnt T; Janich M; Götz U; Gerlach R; Chiricuta IC; Hänsgen G
    Strahlenther Onkol; 2006 Jun; 182(6):325-30. PubMed ID: 16703287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing.
    Rosenthal DI; Chambers MS; Weber RS; Eisbruch A
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):25-8. PubMed ID: 15726519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is there a clinical benefit to adaptive planning during tomotherapy in patients with head and neck cancer at risk for xerostomia?
    You SH; Kim SY; Lee CG; Keum KC; Kim JH; Lee IJ; Kim YB; Koom WS; Cho J; Kim SK; Kim GE
    Am J Clin Oncol; 2012 Jun; 35(3):261-6. PubMed ID: 21383607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
    Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.